MISSISSAUGA, ON / ACCESSWIRE / December 2, 2021 / MedX Health Corp. (TSXV:MDX) ("MedX" or the "Company"), a global leader in teledermatology, will be participating in the SNN Network Canada Virtual Event, taking place virtually December 7th - 9th, 2021.
MedX President Dermatological Services, Mike Druhan, will present the Company's vision for scaling global access to its unique dermatological image capture technology and fully integrated telemedicine platform, DermSecure®. The screening platform features high-resolution image capture technology that enables the accurate evaluation of moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
The conference will be a live, interactive online event where investors are invited to ask the Company questions in real-time. An archived webcast will be made available for attendees who cannot join the event live.
SNN Network Canada Virtual Event 2021
MedX Corporate Presentation
Date & Time: Thursday, December 9 at 12:00 PM ET
Webcast Registration Link: https://www.webcaster4.com/Webcast/Page/2813/43866
To book a one-on-one investor meeting with MedX or to watch the Company presentation, please register for the virtual event here:
https://canada.snn.network/signup
One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.
For those unable to attend the live presentation, all company presentation webcasts will be available directly on the conference event platform on this link under the tab "Agenda": www.canada.snn.network/agenda
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
About SNN.Network
SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create your own watchlist and screen for ideas you're interested in; find out about investor conferences you want to attend - all here on SNN.Network.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bill Mitoulas, Investor Relations
MedX Health Corp.
[email protected]
+1-416-479-9547
SOURCE: MedX Health Corp.